Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors

被引:19
作者
Morita, K
Ono, Y
Fukui, H
Tomita, S
Ueda, Y
Terano, A
Fujimori, T
机构
[1] Dokkyo Univ, Sch Med, Dept Pathol, Mibu, Tochigi 3210293, Japan
[2] Dokkyo Univ, Sch Med, Dept Gastroenterol, Mibu, Tochigi 3210293, Japan
[3] Kyoto Univ, Sch Med, Dept Gastroenterol & Hepatol, Kyoto 606, Japan
关键词
immunohistochemistry; K-ras; ovarian tumors; P53;
D O I
10.1046/j.1440-1827.2000.01028.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Clarification of the pathogenic relationships existing among ovarian cystadenomas, tumors of low malignant potential (LMP) and various adenocarcinoma types, a series of 29 mucinous and 19 serous ovarian tumors including adenomas, LMP tumors and adenocarcinomas were examined, P53 protein was detected by the streptavidin-biotin method and point mutation of K-ras codon 12 was detected by polymerase chain reaction-restriction fragment length polymorphism analysis. P53 overexpression was observed more frequently In serous adenocarcinomas (5/8, 63%) than in mucinous adenocarcinomas (2/9, 22%) and was correlated with the malignant potential of serous tumors. Furthermore, the proportion of P53-positive cells was significantly higher in serous adenocarcinomas than in mucinous adenocarcinomas, P53 overexpression may therefore be closely related to the early events of carcinogenesis in serous tumors, Although mutation of the K-ras oncogene appears to be an important event in the early tumorigenesis of mucinous tumors, mutation of the K-ras oncogene in serous tumors may be dependent on morphology. Different complex pathways of oncogene and/or tumor suppressor gene abnormalities may be involved in the development of mucinous and serous adenocarcinomas.
引用
收藏
页码:219 / 223
页数:5
相关论文
共 32 条
[1]  
Ajiki T, 1996, HEPATO-GASTROENTEROL, V43, P521
[2]   K-ras gene mutation in gall bladder carcinomas and dysplasia [J].
Ajiki, T ;
Fujimori, T ;
Onoyama, H ;
Yamamoto, M ;
Kitazawa, S ;
Maeda, S ;
Saitoh, Y .
GUT, 1996, 38 (03) :426-429
[3]  
[Anonymous], 1998, Armed Forces Institute of Pathology
[4]  
AURE JC, 1971, OBSTET GYNECOL, V37, P1
[5]  
BERCHUCK A, 1990, CANCER RES, V50, P4087
[6]   P53 ACCUMULATION IN OVARIAN CARCINOMAS AND ITS PROGNOSTIC IMPLICATIONS [J].
BOSARI, S ;
VIALE, G ;
RADAELLI, U ;
BOSSI, P ;
BONOLDI, E ;
COGGI, G .
HUMAN PATHOLOGY, 1993, 24 (11) :1175-1179
[7]   Sprouty, an intracellular inhibitor of Ras signaling [J].
Casci, T ;
Vinós, J ;
Freeman, M .
CELL, 1999, 96 (05) :655-665
[8]  
CHARLES J, 1996, GYNECOL ONCOL, V60, P347
[9]  
ENOMOTO T, 1991, AM J PATHOL, V139, P777
[10]  
ENOMOTO T, 1990, CANCER RES, V50, P6139